Compare SSYS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSYS | PCRX |
|---|---|---|
| Founded | 1989 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.7M | 949.9M |
| IPO Year | 2012 | 2010 |
| Metric | SSYS | PCRX |
|---|---|---|
| Price | $7.95 | $25.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $12.33 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 812.1K | 434.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $4.48 | $6.78 |
| Revenue Next Year | $3.23 | $8.54 |
| P/E Ratio | ★ N/A | $138.68 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $7.34 | $18.80 |
| 52 Week High | $12.78 | $27.66 |
| Indicator | SSYS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 54.54 |
| Support Level | $7.49 | $21.97 |
| Resistance Level | $8.24 | $26.94 |
| Average True Range (ATR) | 0.30 | 0.64 |
| MACD | -0.02 | 0.16 |
| Stochastic Oscillator | 36.69 | 69.54 |
Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.